ASMTL and neoplasm: The above studies reveal that the MYC/ASMTL-AS1/miR-342-3p/NLK/YAP regulatory axis plays a crucial role in mediating the malignant biological behaviors of tumor cells after RFA deficiency, which indicates that the combination of targeted therapy against molecular targets can provide support for the prognosis of patients after RFA.